A multivariate Cox proportional hazards model for cyclin A2, cyclin D1, CCND1 status and treatment interaction
| Variable . | . | Recurrence free survival . | . | Overall survival . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | RR (95% CI) . | P . | RR (95% CI) . | P . | |||
| D1 NF | Low versus high | 0.94 (0.62-1.44) | 0.79 | 0.85 (0.54-1.34) | 0.49 | |||
| Treatment | Tamoxifen versus control | 0.67 (0.39-1.12) | 0.13 | 0.67 (0.38-1.19) | 0.17 | |||
| Interaction variable | Tamoxifen × D1 nf | 0.88 (0.44-1.79) | 0.74 | 1.12 (0.53-2.37) | 0.76 | |||
| D1 NI | Low/moderate versus high | 0.80 (0.36-1.74) | 0.57 | 0.96 (0.44-2-20) | 0.92 | |||
| Treatment | Tamoxifen versus control | 0.62 (0.42-0.88) | 0.009 | 0.73 (0.49-1.08) | 0.11 | |||
| Interaction variable | Tamoxifen × D1 ni | 1.18 (0.40-3.50) | 0.77 | 0.84 (0.27-2.58) | 0.76 | |||
| A2 NF | Low versus high | 0.97 (0.58-1.62) | 0.92 | 1.12 (0.65-1.93) | 0.68 | |||
| Treatment | Tamoxifen versus control | 0.48 (0.28-0.82) | 0.007 | 0.68 (0.39-1.19) | 0.18 | |||
| Interaction variable | Tamoxifen × A2 nf | 1.78 (0.83-3.79) | 0.14 | 1.25 (.57-2.75) | 0.58 | |||
| CCND1 | Amplified versus nonamplified | 0.57 (0.27-1.22) | 0.15 | 0.82 (0.30-1.79) | 0.62 | |||
| Treatment | Tamoxifen versus control | 0.39 (0.23-0.65) | <0.001 | 0.41 (0.22-0.75) | 0.004 | |||
| Interaction variable | Tamoxifen × CCND1 | 6.38 (2.29-17.78) | <0.001 | 5.34 (1.84-15.51) | 0.002 | |||
| Variable . | . | Recurrence free survival . | . | Overall survival . | . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | RR (95% CI) . | P . | RR (95% CI) . | P . | |||
| D1 NF | Low versus high | 0.94 (0.62-1.44) | 0.79 | 0.85 (0.54-1.34) | 0.49 | |||
| Treatment | Tamoxifen versus control | 0.67 (0.39-1.12) | 0.13 | 0.67 (0.38-1.19) | 0.17 | |||
| Interaction variable | Tamoxifen × D1 nf | 0.88 (0.44-1.79) | 0.74 | 1.12 (0.53-2.37) | 0.76 | |||
| D1 NI | Low/moderate versus high | 0.80 (0.36-1.74) | 0.57 | 0.96 (0.44-2-20) | 0.92 | |||
| Treatment | Tamoxifen versus control | 0.62 (0.42-0.88) | 0.009 | 0.73 (0.49-1.08) | 0.11 | |||
| Interaction variable | Tamoxifen × D1 ni | 1.18 (0.40-3.50) | 0.77 | 0.84 (0.27-2.58) | 0.76 | |||
| A2 NF | Low versus high | 0.97 (0.58-1.62) | 0.92 | 1.12 (0.65-1.93) | 0.68 | |||
| Treatment | Tamoxifen versus control | 0.48 (0.28-0.82) | 0.007 | 0.68 (0.39-1.19) | 0.18 | |||
| Interaction variable | Tamoxifen × A2 nf | 1.78 (0.83-3.79) | 0.14 | 1.25 (.57-2.75) | 0.58 | |||
| CCND1 | Amplified versus nonamplified | 0.57 (0.27-1.22) | 0.15 | 0.82 (0.30-1.79) | 0.62 | |||
| Treatment | Tamoxifen versus control | 0.39 (0.23-0.65) | <0.001 | 0.41 (0.22-0.75) | 0.004 | |||
| Interaction variable | Tamoxifen × CCND1 | 6.38 (2.29-17.78) | <0.001 | 5.34 (1.84-15.51) | 0.002 | |||
NOTE: Adjusted for age (continuous), tumor size (continuous), NHG (1 + 2 versus 3), and nodal status (0 versus 1).